Our focus areas


Heart Disease

Heart disease is the number one cause of death in Ireland. Cardiovascular disease - including coronary heart disease, stroke and other circulatory problems - causes more than 10,000 deaths a year.
Click here for more information.

MSD is dedicated to combating heart disease and has been producing treatments for it since the 1950s. We remain at the forefront of fighting it, providing our customers with new treatments, improved care and better screening.



Diabetes is a chronic disease and a growing global health issue. The World Health Organisation says 382 million people worldwide have diabetes and predicts that diabetes will be the seventh leading cause of death in 2030.
Click here for more information.

In Ireland, more than 225,000 people are living with diabetes, while an estimated 30,000 more people have it but are undiagnosed. Nearly 150,000 people may have undetected pre-diabetes.
Click here for more information.

Tackling diabetes requires a holistic approach, including lifestyle changes. We work closely with professional and patient groups to improve patient education on managing the condition. Working with Diabetes Ireland, for example, we have helped to deliver a number of disease awareness campaigns and patient information booklets.


Cancer is one of the world's most urgent unmet medical needs.  Our goal is to translate breakthrough science into biomedical innovations to help people with cancer in Ireland and worldwide. 

MSD is committed to developing therapies to treat cancer and make a meaningful difference to the lives of patients with cancer. Harnessing immune mechanisms to fight cancer is the main focus of our oncology research and development program. 

Hepatitis C and HIV/Aids

In developing new treatments for infectious diseases, we work with health service providers, academic researchers and patient support organisations. We focus on:

Hepatitis C

The World Health Organisation estimates that 3% of the world’s population is infected with Hepatitis C, a virus that is transmitted through infected blood and can cause chronic liver disease. It’s known as the ‘silent’ epidemic because those infected often don’t show symptoms for many years.

MSD has been working on Hepatitis C research and treatment for 30 years, and now has a new class of medicine that helps patients with the hardest-to-treat form of Hepatitis C.


For more than 25 years we have been at the forefront of the global response to the HIV and AIDS epidemic. MSD scientists were among the first to discover and develop medicines for HIV.

Today, we continue to play a leading role in the development of improved medicines and therapies to help patients, families and carers affected by the condition.


Vaccines are one of the greatest public health success stories of the past century, and MSD has played its part in that story.

We are one of a few companies that remain dedicated to the complex business of researching and producing vaccines. Our contributions include the prevention of now-rare diseases, like measles and mumps, to vaccines for diseases never thought preventable, like shingles and cervical cancer.

*In Ireland, Sanofi Pasteur MSD markets all vaccines developed by MSD.